National and Kapodistrian University of Athens
Ανίχνευση και χαρακτηρισμός μεγάλων γονιδιακών αναδιατάξεων στα γονίδια brca1 και brca2 σε οικογένειες με κληρονομικό καρκίνο μαστού / ωοθηκών
Abstract
dc:descriptionBreast cancer is the most commonly occurring cancer among women and the second leading cause of cancer - related deaths in women in western world. The estimated annual incidence of breast cancer worldwide is about one million cases. Ovarian cancer accounts for 4% of all cancers in women. In 1997, almost 26.700 new cases were diagnosed and almost 14.800 women died of the disease in the United States. An estimated 10% of all breast cancer cases and 8% of all ovarian cancer cases are hereditary. Two breast/ovarian cancer susceptibility genes (BRCA1 and BRCA2) have been mapped and cloned. Early genetic linkage studies using multiple case families have suggested that mutations in the BRCA1 and BRCA2 genes account for 45% of hereditary breast cancer and 80 - 90% of breast and ovarian cancer. Based on some of these studies, it was determined that BRCA1 mutation carriers had a lifetime risk of 60 - 85% for breast cancer and almost half this percentage for ovarian cancer by the age of 70. For BRCA2 the relevant proportion is the same as for BRCA1 gene concerning the risk of breast cancer development, whereas much smaller concerning ovarian cancer. Moreover, in the case the disease is developed in older patients. The BRCA1 mutational spectrum is very complex and the identification of these mutations has a very important diagnostic value. The presence of genomic rearrangements of the BRCA1 and BRCA2 genes in breast and/or ovarian cancer families has been intensively investigated in patients from various countries over the last years. Germline genomic rearrangements have been found to be the cause of development of a variety of human genetic disorders, including several cancer - susceptibility syndromes. Since 1997, when the first genomic rearrangement of BRCA1 was described, it has been shown that genomic rearrangements make a significant contribution to the mutation spectrum of BRCA1. The proportion of BRCA1 mutations due to genomic rearrangements ranges in different countries from 4% to 20% except when a founder effect results in a mutated allele with a high frequency. The proportion of BRCA2 mutations due to genomic rearrangements is lower and ranges from 2% to 11%. The purpose of the present work was the identification and characterization of genomic rearrangements in BRCA1 and BRCA2 genes as well as the contribution of those rearrangements in the development of cancer in Greek patients with breast/ovarian cancer. Two different technical approaches were applied: Quantitative Multiplex PCR of Short Fluorescent fragments (QMPSF) and Multiplex Ligation-dependent Probe Amplification (MLPA). Two different large genomic rearrangements in BRCA1 gene were detected by QMPSF in two unrelated families in a cohort of 112 unrelated families with breast/ovarian cancer history analyzed. The first rearrangement detected includes an approximately 4 kb deletion involving exon 20 of BRCA1 gene, whereas the second one includes an approximately 4.5 kb deletion involving exon 24 and the 3΄- untranslated region of the BRCA1 gene. Those large deletions were confirmed by long - range PCR and characterized by direct sequencing. Both of them are novel. The mutation effect of the 4.5 kb deletion was the complete loss of the mutant transcript. This was found by cSNP genotyping. In order to estimate the frequency of genomic rearrangements in Greek patients with breast/ovarian cancer, diagnostic primers were designed. A number of 86 unrelated families with breast ovarian cancer history and 210 sporadic breast cancer patients were examined using these diagnostic primers. The exon 24 deletion was detected in an additional unrelated family with breast/ovarian cancer history. Moreover, a different exon 20 genomic rearrangement was detected in a sporadic breast cancer patient. This last rearrangement involved a 3.2 kb deletion including exon 20 which has been described once more, also in a Greek patient. Conclusively, the contribution of genomic rearrangements in Greek patients with breast/ovarian cancer accounts for approximately 10% of all BRCA1 mutations. A cohort of 81 unrelated families with breast cancer history was examined for BRCA2 large genomic rearrangements using the technique MLPA. No genomic rearrangements were detected in this case. This last result is in agreement with other population studies (e.g in Netherlands, Germany, Denmark and Finland) where no rearrangements were detected.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2007
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Armaou, Sophia
- Αρμάου, Σοφία
Subjects
dc:subject × 20Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/18374